A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of CAD-1883 in Healthy Subjects

Published: 10-01-2018 Last updated: 12-04-2024

Primary objectivesPart 1:* To evaluate the safety and tolerability of escalating single oral doses of CAD-1883 in healthy male subjects.Part 2:* To determine the effect of food on the PK profile of a single oral dose of CAD-1883 in healthy female...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Movement disorders (incl parkinsonism)
Study type	Interventional

Summary

ID

NL-OMON46676

Source ToetsingOnline

Brief title CS0289 (CAD1883-101)

Condition

• Movement disorders (incl parkinsonism)

Synonym

movement disorders

Research involving

1 - A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to ... 29-04-2025

Human

Sponsors and support

Primary sponsor: Cadent Therapeutics, Inc. **Source(s) of monetary or material Support:** Cadent Therapeutics;Inc.

Intervention

Keyword: Pharmacokinetic, Safety, Tolerability

Outcome measures

Primary outcome

Safety (AEs, VS, Physical examination, Clinical laboratory assessments, ECG,

telemetry)

PK (Cmax, Tmax, AUC0-t, AUC0-inf)

Secondary outcome

PK (Cmax, Tmax, AUC0-t, AUC0-inf)

Safety (AEs, VS, Physical examination, Clinical laboratory assessments, ECG,

telemetry)

Study description

Background summary

Cadent Therapeutics, Inc. is developing CAD-1883 for the treatment of spinocerebellar ataxia (SCA) and essential tremor (ET).

CAD-1883 is a novel small molecule positive allosteric modulator of SK channels that has been shown to regulate Purkinje cell firing in cerebellar brain slices. It furthermore reduced measures of ataxic gait in mouse models of autosomal-dominant hereditary ataxia and reduced tremor in the rat harmaline tremor model.

The proposed study is intended to assess the safety, tolerability and pharmacokinetic (PK) profile of single and repeated oral doses of CAD-1883 in

healthy subjects. In particular, this clinical trial will evaluate the safety and tolerability of escalating single oral doses of CAD-1883 in healthy male subjects, evaluate PK of a single oral dose of CAD-1883 and the effect of food on the PK of CAD-1883 in healthy female subjects, and evaluate the safety and tolerability of escalating multiple oral doses of CAD-1883 in healthy male subjects. The safety, tolerability, and pharmacokinetics of CAD-1883 observed in this study are intended to inform the design of subsequent Phase 1 studies in SCA and ET patients.

Study objective

Primary objectives

Part 1:

* To evaluate the safety and tolerability of escalating single oral doses of CAD-1883 in healthy male subjects.

Part 2:

* To determine the effect of food on the PK profile of a single oral dose of CAD-1883 in healthy female subjects.

Part 3:

* To evaluate the safety and tolerability of escalating multiple oral doses of CAD-1883 in healthy male subjects.

Part 1:

* Cohort 1:1 to 1:4 and cohort 1:6: To determine the PK profile of single oral doses of CAD-1883 in healthy male subjects.

* Cohort 1:5 only: To determine the PK profile of a twice daily oral dose of CAD-1883 in healthy male subjects.

* Cohort 1:6 only: To correlate CAD-1883 exposure in CSF with plasma exposure in healthy male subjects.

Part 2:

 \ast To determine the effect of food on the safety and tolerability of CAD-1883 in healthy female subjects.

Part 3:

* To determine the PK profile of multiple oral doses of CAD-1883 in healthy male subjects.

Study design

This study is a randomized, placebo-controlled phase 1 study in three parts: single ascending doses or two doses administered 12 hours apart in males (Part 1), food effect in females (Part 2), and multiple ascending doses in males (Part 3). Parts 1 and 3 are double-blind, Part 2 is both double-blind (Period 3) and open-label (Period 1 and Period 2).

Intervention

CAD-1883 Matching placebo

Study burden and risks

This study is being conducted in healthy volunteers. There are no anticipated benefits of the IMP. Please see the IMP information (IB) for further information.

Contacts

Public Cadent Therapeutics, Inc.

Technology Square 400 Cambridge MA 02139 US **Scientific** Cadent Therapeutics, Inc.

Technology Square 400 Cambridge MA 02139 US

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Healthy male and female

Exclusion criteria

Clinical significant abnormalities at medical research

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	30-01-2018
Enrollment:	128
Туре:	Actual

Ethics review

Approved WMO	
Date:	10-01-2018
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO

Date:	17-01-2018
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	22-02-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO	23-02-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	22-03-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	23-03-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	05-04-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	06-04-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	09-04-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

6 - A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to ... 29-04-2025

	(Assen)
Approved WMO Date:	11-04-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	17-08-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO	
Date:	03-09-2018
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register
EudraCT
ССМО

ID EUCTR2017-004223-70-NL NL64205.056.17